Andreas Wicki

Andreas Wicki is the Chief Executive Officer of HBM Partners AG, a position he has held since 2004.1 He is a prominent figure in the healthcare investment sector with extensive experience in the industry. Here are some key details about Andreas Wicki:

Professional Background

Andreas Wicki has been serving as the CEO of HBM Healthcare Investments AG since 2001.1 He also holds the position of Chief Executive Officer at HBM Healthcare Investments (Cayman) Ltd. since 2001.1 His long tenure in these roles demonstrates his expertise and success in healthcare investments.

Education and Expertise

Dr. Wicki holds a doctorate in chemistry and biochemistry.2 This scientific background has likely contributed to his understanding of the healthcare and biotechnology sectors, enabling him to make informed investment decisions.

Career History

Before his current roles, Dr. Wicki had a diverse career in the pharmaceutical industry:

• He served as the chief executive of several pharmaceutical companies from 1988 to 2001.2
• He also worked as an investment and venture capital advisor from 1993 to 2001.2

Board Positions

Andreas Wicki holds several board positions, showcasing his influence in the healthcare industry:

• Member of the Board of Directors at Harmony Biosciences since 20172
• Director at Pacira Biosciences, Inc. since 200612
• Director at HBM Healthcare Investments (Cayman) Ltd. since 20012
• Director at Buchler GmbH (FAGUS Group) since 20002

Investment Philosophy

Under Dr. Wicki's leadership, HBM Partners focuses on venture, growth, and buy-out financings of private companies, as well as investments in public companies in the biopharma, medtech, diagnostics, and healthcare sectors.3 The firm has a global reach, investing in Europe, North America, India, China, and other emerging markets.3

Andreas Wicki is known for his pioneering approach to financing genetic engineering over 20 years ago and has grown with the field over time.4 His expertise and vision have contributed to HBM Partners' track record of over 100 investments, resulting in more than 60 trade sales and IPOs with significant value creation.3